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Objective: To evaluate the distribution of acquired resistance in  isolates of Mycobacterium tuberculosis from treated 
patients in two periods, 1984-89 and 1990-95, in the Bursa (Southern Marmara) region. 
Method: Susceptibility of 531 M. tuberculosis isolates to  four commonly used drugs (isoniazid (INH), streptomycin (SM), 
ethambutol (EMB) and rifarnpin (RMP)) was determined by the absolute concentration method of Canetti et al. 
Results: In 203 strains isolated in the years 1984-89, the total acquired resistance was 32.5%, and it was 37.5% in 328 
strains isolated in  1990-95 ( p 0 . 0 5 ) .  Resistance to  INH, SM, RMP and EM6 was found in  23.6%, 16.7%, 6.4% and 3.9%, 
respectively, in the first period (1984-89), and in 26.2%. 20.4%, 25.3% and 8.2%, respectively, in the second period 
(1990-95). The increase in RMP resistance was statistically significant (p<O.OOI). The incidence of multidrug-resistant 
strains was 12.3% in the first period, and 24.4% in the second period, a significant increase (p<O.OOI ). 
Conclusions: We believe that progressive emergence of phenotypes resistant to INH+RMP in our region is caused by 
inadequate treatment for various reasons. In the present study, the fact that rnultidrug resistance occurred in nearly 25% 
of patients treated previously but still infective suggests that the approach to surveillance, patient therapy and follow- 
up programs should be fundamentally reconsidered in our region. 
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Tuberculosis, with over 8 million new cases and with 3 
million deaths worldwide each year, constitutes a major 
health problem for almost every country and especially 
for developing countries [I]. It is also an important 
health problem for our country. Currently, it is esti- 
mated that there are more than 250 000 tuberculosis 
patients in Turkey [2]. Tuberculosis has escalated alarm- 
ingly in immunocompromised patients, such as human 
immunodeficiency virus (H1V)-infected cases, in some 
countries, and multidrug-resistant tuberculosis has 
become a serious problem since the end of the 1980s 
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[3-71. Also, it is notable that there have been recent 
publications and presentations at  national congresses 
that indicate a marked increase in multidrug-resistant 
cases in Turkey [8,9].  
In this retrospective study, we made a comparative 
investigation into the distribution of resistance in the 
Mycobacteriurn tuberculosis isolates from patients treated 
in the Southern Marmara Region, during two different 
periods: 1984-89 and 1990-95. 
MATERIALS AND METHODS 
Acquired resistance was sought in isolates from adult 
patients who had received treatment for pulmonary 
tuberculosis, diagnosed at least 2 months previously, but 
whose treatment was known to have been irregular or 
discontinued early, and who had remained culture 
positive throughout the period. In total, 531 individual 
patient isolates obtained from sputum samples referred 
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from the Pulmonary Diseases Department and 
Tuberculosis Dispensaries to the Microbiology 
Laboratory, Medical Faculty, Uludag University, were 
included, 203 obtained between 1984 and 1989, and 
328 obtained between 1990 and 1995. Repeat isolates 
from the same patients were excluded, and no patient 
was represented in both periods. 
For the isolation of M.  tuberculosis, sputum samples 
were inoculated onto Lowenstein-Jensen medium 
following standard techniques, and the culture tubes 
were incubated for 8 weeks at 37"C, with inspection 
weekly for growth. Non-pigmented, dry, rough 
colonies, with a nodular surface and an irregular thin 
periphery, were obtained within 3-6 weeks (mean 4 
weeks). For identification, standard biochemical tests 
were used [lo]. 
The susceptibility of isolated M. tuberculosis strains 
to isoniazid (INH), streptomycin (SM), ethambutol 
(EMB) and rifampin (RMP) was determined by the 
absolute concentration method of Canetti et al [I 1-13]. 
Lowenstein-Jensen medium was used in the test. 
From a suitable dilution of bacteria mg/mL to 
mg/mL), 0.2 mL was taken and inoculated onto 
drug-containing and drug-free control medium. 
Preparation of the culture medium, drug dilutions and 
inoculum was according to standard methods. The 
drug concentrations used in the test, as proposed by 
Canetti et al, are presented in Table 1 [11,12]. From a 
medical viewpoint, tubercle bacilli are classified as 
resistant with respect to the critical drug concentration 
beyond which treatment is no longer effective. These 
critical concentrations have been empirically estab- 
lished for most drugs used in therapy, as indicated in 
Table 1 [11,12,14,15]. Following incubation, the 
isolates were considered to be resistant if there was 
more than 1% growth on medium containing anti- 
tuberculous drugs as compared with the growth on 
drug-free medium. 
Statistical analysis 
Proportions were compared by chi-squared test with 
Yates correction or by Fisher's exact test as necessary. 
Statistical testing was done with Epi Info, a software 
Table 1 Graded concentrations of antituberculous drugs in 
Lowenstein-Jensen medium 
Drug Concentrations of drugs (mg/L) 
INH 0.1 
SM 2 
EMB 2.5 
RMP 10 
0.2 
4 
5 
20 
1 
8 
10 
40 
The values in the second column indicate critical drug 
concentrations. 
Table 2 Pattern of single-drug and multidrug resistance to 
antituberculous drugs in two different periods 
1984-89 1990-95 
(n=328) (n=203) 
Resistant Resistant 
strain stram 
Drug n %  n % pvalue 
(A) Single-drug resistance 
INH 24 11.8 11 3.3 
SM 12 5.9 15 4.6 
RMP 4 2.0 17 5.2 
EMJ3 1 0.5 0 0  
Total 41 20.2 43 13.1 
(B) Multidrug resistance 
INH+SM 13 6.4 12 3.7 
INH+RMP 1 0.5 20 6.1 
INHfEMB 1 0.5 2 0.6 
SM+RMP 1 0.5 2 0.6 
RMP+EMB 0 0  2 0.6 
Total (two drugs) 16 7.9 38 11.6 
INH + SM+FUvlP 3 1.5 19 5.8 
INH+RMP+EMB 1 0.5 4 1.2 
INH+SM+EMB 2 1.0 0 0  
RMP+ SM+EMB 0 0  1 0.3 
Total (three drugs) 6 3.0 24 7.3 
INH+SM+RMP+EMB 3 1.5 18 5.5 
Total multidrug resistance 25 12.3 80 24.4 
<0.001 
>0.05 
>0.05 
20.05 
<0.05 
>0.05 
<0.01 
10.05 
>0.05 
>0.05 
>0.05 
<0.05 
>0.05 
>0.05 
>0.05 
C0.05 
10.05 
<0.001 
package developed by the CDC. AU p values are two- 
tailed and considered significant if less than 0.05 
[ 16,171. 
The results are displayed in Table 2. While the total 
acquired resistance rate was 32.5% (66/203) in 203 M. 
tuberculosis isolates in the first period, this rate was found 
to be 37.5% (123/328) in 328 isolates in the second 
period. This increase is not statistically significant 
(p>0.05). The rate of resistance to INH and SM was 
high during the first period (23.6% and 16.7% 
respectively) but resistance to RMP and EMB was 
lower (6.4% and 3.9% respectively). In the second 
period, however, resistance to INH and SM was 26.2% 
and 20.4% respectively, and there seemed to be 
increases in resistance to RMP and EMB (25.3% and 
8.2% respectively). So far, only the increase in resistance 
to RMP is significant (p<O.OOl). 
Although resistance to a single drug was 20.2% in 
the first period, it was only 13.1% in the second period 
(pC0.05) (Table 2(A)). As for multidrug resistance, it 
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was 12.3% in the first period, and 24.4% in the second 
period, the rate of increase being significant (p<0.05) 
(Table 2(B)). 
DISCUSSION 
A national campaign against tuberculosis was started in 
the 1940s by the Turkish government. Tuberculosis was 
included in the category of diseases to be reported, the 
National Society for Tuberculosis was established in 
1948 and the campaign against this disease was sup- 
ported by three new laws. In 1952, the Ministry of 
Health, in collaboration with the National Society for 
Tuberculosis, WHO and UNICEF, started a nation- 
wide BCG campaign. As a result, 63% of the popu- 
lation (90% of the younger population) was immunized 
with BCG between 1953 and 1983. In Turkey, all 
newborn babies are still immunized with BCG. During 
the period 1960-77, a nationwide chest X-ray screening 
program was conducted, new hspensaries and hospitals 
for tuberculosis were opened and tuberculosis patients 
were treated and followed up at outpatient and in- 
patient departments. 
As a result of this intensive struggle, which may set 
a precedent in this field for developing countries, the 
death rate from tuberculosis decreased 30 times, drop- 
ping from 260 deaths per 100 000 people in 1945, to 
8.8 per 100 000 in the 1980s. Nevertheless, tubercu- 
losis is still one of the leading causes of death in Turkey 
In Turkey, relatively short-term treatment regi- 
mens (9 months) for pulmonary tuberculosis (2 months 
of INH-RMP-pyrazinamide-SM or EMB and 7 
months of INH-RMP) have generally been used since 
1987. However, different treatment regimens are used 
according to the characteristics of the cases. Our 
patients are made up of chronic or recurrent cases who 
had been treated for at  least 2 months in the recent past 
but whose treatment was irregular or discontinued for 
various reasons. 
Primary resistance is resistance of the bacilli with 
which new patients are infected [19]. As the patients in 
Turkey may not provide definitive and reliable inform- 
ation regarding their previous medical history, mistakes 
are frequently made in establishing primary resistance. 
In daily medical practice in developing countries, the 
possibility that the patient has received antituberculosis 
drugs previously cannot be excluded [9]. For this 
reason, we have concentrated on secondary drug resist- 
ance patterns in our patients. Acquired (secondary) 
drug resistance is resistance which has emerged during 
the course of chemotherapy, provided that the sputum 
has remained consistently culture-positive [ l  11. 
Secondary resistance in M.  tuberculosis reflects the 
[181. 
quality of the chemotherapy applied in the community 
[20]. Acquired (secondary) resistance may emerge as 
multidrug resistance under selective pressure, especially 
when chemotherapy is irregular and inadequate [4,14]. 
Our  findings show that the rate of secondary 
resistance to antituberculous drugs is rather high in the 
Marmara Region (32.5% in the first period and 37.5% 
in the second period). These figures are in accordance 
with other reports published in Turkey [8,9,21]. In 
addition, it is observed that multidrug resistance in our 
region has significantly increased in the second period 
(Table 2(B)). HIV infection and drug addiction in 
Turkey are far from explaining this increase. Further- 
more, there was no epidemic of tuberculosis in the area. 
In Turkey, tuberculosis constitutes a serious danger 
for a population whose socio-economic situation is not 
good and whose education is limited. Poor compliance 
of the patients with long-term therapy, consideration of 
tuberculosis as a shameful disease by young people in 
Anatolia and the habit of concealing it from the 
neighborhood may be important reasons both for 
recurrence and easy transmission of the disease and for 
development of multidrug resistance. 
While the total frequency of resistance to INH was 
similar in the two periods (23.6% in the first period and 
26.2% in the second period; p>0.05), the decrease in 
single-drug resistance for INH from 11.8% to 3.3% 
within the second period (Table 2(A)) can be 
accounted for mostly by the incorporation of this 
resistance into the pattern of multidrug resistance 
(p<O.Ol) (Table 2(B)). While the difference in the 
single-drug resistance to R M P  between the two 
periods is not significant (Table 2(A)), in the second 
period the rate of multiple resistance to R M P  signi- 
ficantly increased from 4.4% (9/203) to 20% (66/328) 
(p<O.OOl) (Table 2(B)). l N H + R M P  resistance, which 
was 3.9% (8/203) in the first period, increased to 18.6% 
(61/328) in the second period (Table 2(B)), which 
indicated that multidrug resistance mainly depended on 
the INH+RMP combination in the period after 1990 
(approximately 75% of multidrug-resistant strains). 
In M.  tuberculosis, development of high-level 
resistance to R M P  occurs in a single step [22]. Since 
most strains with multidrug resistance show this high- 
level resistance, R M P  resistance is suggested as a marker 
for multidrug resistance [23]. Resistance to INH and 
RMP, the most effective drugs, is of great significance 
in modern antituberculosis chemotherapy, because this 
resistance greatly reduces the effectiveness of the 
standard chemotherapeutic regimens [24,25]. These 
multidrug-resistant strains may create a risk of epi- 
demics in the community [26]. 
It is also possible that the common use of R M P  in 
the treatment of brucellosis, which is endemic in our 
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region, and in the chemoprophylaxis of meningococcal 
meningitis, may have contributed to FWlP resistance 
overall. The fact that multidrug resistance was found in 
nearly 25% of patients who had been treated previously 
but were still infective suggests that the approach to 
surveillance, patient therapy and follow-up programs 
should be fundamentally reconsidered in our region. 
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